The Novel Sinupret® dry extract BNO 1011 inhibits paw oedema development in vivo and inflammatory mediator release in vitro

Inflammatory processes are important therapeutic targets in the treatment of rhinosinusitis. The novel dry extract BNO 1011 is based on the Sinupret® drug mixture (Gentianae radix, Primulae flos, Sambuci flos, Rumicis herba, and Verbenae herba), an herbal medicinal product to treat rhino-sinusitis. The anti-inflammatory activity of BNO 1011 was investigated in the rat paw oedema model of acute inflammation and potential underlying mechanisms were studied in vitro. In rats, carrageenan-induced oedema development was significantly reduced after oral application of BNO 1011. In vitro, BNO 1011 was able to reduce prostaglandin biosynthesis by COX-1 and COX-2 enzymes and inhibited leukotriene B₄ secretion, mediators known to contribute to inflammation of the upper and lower airways. The T-cell mediated release of pro-inflammatory IFN-γ was also reduced. Taken together, Sinupret® dry extract BNO 1011 was proven to reduce inflammation in vivo, most likely by targeting the release of pro-inflammatory mediators. The anti-inflammatory action of BNO 1011 supports its role in the treatment of rhinosinusitis, an infectious condition accompanied by inflammation of nasal and paranasal mucosal tissues.